Login / Signup

Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety.

Frederick M LangSergio TeruyaAriel WeinsaftMargaret CuomoAlfonsina Mirabal SantosAni NalbandianDimitrios BampatsiasMathew S Maurer
Published in: European journal of heart failure (2024)
Sodium-glucose cotransporter 2 inhibitors were well tolerated by most patients with ATTR-CM and appeared to improve volume status and combat diuretic resistance. Randomized studies are needed to confirm these findings.
Keyphrases
  • double blind
  • heart failure
  • open label
  • placebo controlled
  • randomized controlled trial